A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

July 21, 2015

Primary Completion Date

November 24, 2016

Study Completion Date

November 24, 2016

Conditions
Asthma
Interventions
DRUG

Interferon beta-1a Nebuliser solution 48 μg/mL

Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days

DRUG

Placebo

Placebo solution for once daily inhalation for 14 days

Trial Locations (35)

1426

Research Site, Ciudad Autonomade Buenos Aires

2145

Research Site, Westmead

2310

Research Site, New Lambton

4102

Research Site, Woolloongabba

5042

Research Site, Bedford Park

13015

Research Site, Marseille

14584

Research Site, Bucheon-si

21079

Research Site, Dijon

29010

Research Site, Málaga

29603

Research Site, Marbella (Málaga)

33604

Research Site, Pessac

34295

Research Site, Montpellier

41071

Research Site, Seville

46017

Research Site, Valencia

54907

Research Site, Jeonju

69317

Research Site, Lyon

75877

Research Site, Paris

110311

Research Site, Bogotá

680006

Research Site, Floridablanca

C1414AIF

Research Site, Buenos Aires

C1425BEN

Research Site, CABA

B6500EZL

Research Site, Nueve de Julio

B1878FNR

Research Site, Quilmes

Unknown

Research Site, Bogotá

02559

Research Site, Seoul

03080

Research Site, Seoul

05505

Research Site, Seoul

08003

Research Site, Barcelona

FY4 3AD

Research Site, Blackpool

BD9 6RJ

Research Site, Bradford

LA1 4RP

Research Site, Lancaster

LS9 7TF

Research Site, Leeds

M23 9QZ

Research Site, Manchester

NG5 1PB

Research Site, Nottingham

SO9 4XY

Research Site, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY